Restarting Citalopram in an 80-Year-Old Man
In an 80-year-old man previously taking citalopram 20 mg daily, restart at 10 mg daily and do not exceed 20 mg daily maximum dose due to age-related QT prolongation risk and increased drug exposure.
Critical Age-Related Dosing Restrictions
The FDA drug label explicitly states that 20 mg/day is the maximum recommended dose for patients greater than 60 years of age due to QT prolongation risk 1. This restriction is particularly important for your 80-year-old patient, as:
- Citalopram plasma levels are 55% higher in patients ≥80 years compared to younger adults at the same dose 2
- Elderly patients (73-90 years) show steady-state levels up to four times higher than expected from younger patient data, with biological half-lives of 1.5-3.75 days versus 1.5 days in younger individuals 3
- Age accounts for 18% of the variability in citalopram plasma levels 2
Restart Protocol
Starting Dose
Begin with 10 mg once daily rather than immediately returning to the previous 20 mg dose. This conservative approach allows you to:
- Assess current tolerability given age-related pharmacokinetic changes
- Monitor for QT prolongation and cardiac effects
- Evaluate for drug interactions with any new medications started since discontinuation
Titration Schedule
If 10 mg is well-tolerated after 1-2 weeks and clinical response is inadequate:
- Increase to 20 mg daily (the maximum allowable dose for this age group)
- Do not exceed 20 mg daily under any circumstances 1
Essential Monitoring
Before restarting:
- Obtain baseline ECG to assess QTc interval
- Review all current medications for QT-prolonging drugs or CYP2C19 inhibitors
- Check renal function (though mild-moderate impairment doesn't require dose adjustment) 1
After restarting:
- Monitor for discontinuation syndrome symptoms if there was a recent abrupt stop (dizziness, fatigue, nausea, myalgias, anxiety) 4
- Repeat ECG after reaching steady state (approximately 1 week) to assess QTc changes 5
- Monitor for serotonin syndrome symptoms, especially in first 24-48 hours if combining with other serotonergic drugs 4
Critical Safety Considerations
QT Prolongation Risk
Citalopram causes dose-dependent QT prolongation with risk of Torsades de Pointes, ventricular tachycardia, and sudden death at doses exceeding 40 mg/day in younger patients 4. The FDA and EMA have specifically reduced maximum doses for patients >60 years based on QT studies 5. Your patient at age 80 has:
- Increased cardiac arrest risk (OR 1.21 for SSRIs overall) 5
- Higher plasma concentrations at standard doses 2, 3
- Reduced metabolic clearance 3
Drug Interactions
If the patient is taking cimetidine or other CYP2C19 inhibitors, the maximum dose is further restricted to 20 mg/day (which is already the age-based maximum) 1. CYP2C19 poor metabolizers show 107% increased AUC, warranting the same 20 mg maximum 1.
Gradual Discontinuation Principle
If the patient recently stopped citalopram abruptly, be aware that discontinuation syndrome can occur with shorter-acting SSRIs like citalopram 4. Symptoms include dizziness, fatigue, nausea, anxiety, and irritability. One case report even documented new-onset hypertension following abrupt citalopram cessation 6.
Common Pitfalls to Avoid
- Do not restart at the previous 20 mg dose immediately - start lower given age-related pharmacokinetic changes
- Do not exceed 20 mg daily regardless of previous tolerance or clinical response
- Do not combine with MAOIs - allow at least 14 days between stopping an MAOI and starting citalopram 1
- Do not ignore concomitant QT-prolonging medications - citalopram especially interacts with drugs that prolong QT interval 4
- Do not assume previous tolerance guarantees current safety - cardiac conduction changes and drug interactions may have developed
Timing Considerations
Administer once daily, morning or evening, with or without food 1. If the patient had previously taken it at a specific time with good adherence, maintain that schedule for consistency.